Second breast-conserving surgery and interstitial brachytherapy vs. salvage mastectomy for the treatment of local recurrences: 5-year results
The purpose of this study was to report the clinical outcomes of a second breast-conserving therapy (2nd BCT) with perioperative interstitial brachytherapy (iBT) vs. those of salvage mastectomy (sMT) in the treatment of ipsilateral breast tumor recurrences (IBTRs). (Source: Brachytherapy)
Source: Brachytherapy - March 16, 2019 Category: Cancer & Oncology Authors: Viktor Smanyk ó, Norbert Mészáros, Mihály Újhelyi, Georgina Fröhlich, Gábor Stelczer, Tibor Major, Zoltán Mátrai, Csaba Polgár Source Type: research

Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms
To evaluate the long-term urinary outcomes of men with severe pretreatment lower urinary tract symptoms (LUTS) treated with permanent prostate brachytherapy (PPB)  ± external beam radiation therapy for localized prostate cancer. (Source: Brachytherapy)
Source: Brachytherapy - March 16, 2019 Category: Cancer & Oncology Authors: Jared S. Winoker, Rollin K. Say, Reza Mehrazin, Richard G. Stock, Nelson N. Stone Source Type: research

Brachytherapy: Expanding the horizons
This special edition of brachytherapy will focus on intraoperative radiation therapy and electronic brachytherapy. The purpose of this special edition is to highlight these techniques and make our readership and authors aware that we are broadening the scope and purview of the journal to include these modalities. Intraoperative radiation therapy, whether delivered with high-dose-rate, low-dose-rate, electronic, or other techniques is consistent with brachytherapy as a technique as it places radiation therapy close to tumors/tumor beds, offering the ability to maximize the therapeutic ratio by delivering high doses to the t...
Source: Brachytherapy - March 16, 2019 Category: Cancer & Oncology Authors: Chirag Shah, Michael J. Zelefsky Tags: Editorial Source Type: research

Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer
This study aimed to test the hypothesis that patients with prostate cancer with intermediate- or high-risk disease undergoing extreme dose escalation with a brachytherapy boost are less likely to receive ADT. (Source: Brachytherapy)
Source: Brachytherapy - March 9, 2019 Category: Cancer & Oncology Authors: Jahan J. Mohiuddin, Vivek Narayan, Sriram Venigalla, Neha Vapiwala Source Type: research

Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds
Pulmonary seed emboli to the chest may occur after permanent prostate brachytherapy (PPB). The purpose of this study is to analyze factors associated with seed migration to the chest in a large series of PPB patients from a single institution undergoing implant with either loose seeds (LS), mixed loose and stranded seeds (MS), or exclusively stranded seeds in an absorbable vicryl suture (VS). (Source: Brachytherapy)
Source: Brachytherapy - March 7, 2019 Category: Cancer & Oncology Authors: Kenneth W. Merrell, Brian J. Davis, Christopher C. Goulet, Keith M. Furutani, Lance A. Mynderse, W. Scott Harmsen, Torrence M. Wilson, Robert H. McLaren, Christopher L. Deufel, Brandon J. Birckhead, Ryan K. Funk, Brendan P. McMenomy, Bradley J. Stish, C. Source Type: research

Intraoperative brachytherapy for resected brain metastases
Brain metastases are the most common intracranial malignancies in adults. Surgical resection is the preferred treatment approach when a pathological diagnosis is required, for symptomatic patients who are refractory to steroids, and to decompress lesions causing mass effect. Radiotherapy is administered to improve local control rates after surgical resection. After a brief review of the literature describing the treatment of brain metastases using whole-brain radiotherapy, postoperative stereotactic radiosurgery, preoperative radiosurgery, and brachytherapy, we compare patient-related, technical, practical, and radiobiolog...
Source: Brachytherapy - March 5, 2019 Category: Cancer & Oncology Authors: Sean S. Mahase, Kristina Navrazhina, Theodore H. Schwartz, Bhupesh Parashar, A. Gabriella Wernicke Tags: Review Article Source Type: research

Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone
We report long-term survival and toxicity data in a cohort of patients treated in a single institution. (Source: Brachytherapy)
Source: Brachytherapy - March 4, 2019 Category: Cancer & Oncology Authors: Aaron R. Kent, Bronwyn Matheson, Jeremy L. Millar Source Type: research

Implementation of an HDR brachytherapy –based breast IORT program: Initial experiences
This report summarizes our program's experience developing and implementing PB-IORT. (Source: Brachytherapy)
Source: Brachytherapy - March 4, 2019 Category: Cancer & Oncology Authors: Sunil W. Dutta, J. Hunter Mehaffey, Jason C. Sanders, Max O. Meneveau, Courtney Lattimore, Bruce Libby, David R. Brenin, Anneke T. Schroen, Einsley M. Janowski, Carl Lynch, Donna J. Lash, Timothy N. Showalter, Shayna L. Showalter Source Type: research

Novel intraoperative radiotherapy utilizing prefabricated custom three-dimensionally printed high-dose-rate applicators
Intraoperative radiotherapy (IORT) is an effective strategy for the delivery of high doses of radiotherapy to a residual tumor or resection cavity with relative sparing of nearby healthy tissues. This strategy is an important component of the multimodality management of pediatric soft tissue sarcomas, particularly in cases where patients have received prior courses of external beam radiotherapy. (Source: Brachytherapy)
Source: Brachytherapy - February 22, 2019 Category: Cancer & Oncology Authors: Brandon S. Imber, Suzanne L. Wolden, Hilda E. Stambuk, Evan Matros, Leonard H. Wexler, Alexander S. Drew, Evan B. Rosen, Ian Ganly, Gil ’ad N. Cohen, Antonio L. Damato Source Type: research

Radiobiological optimization comparison between pulse-dose-rate and high-dose-rate brachytherapy in patients with locally advanced cervical cancer
Only scarce data are available on the possibility to include radiobiological optimization as part of the dosimetric process in cervical cancer treated with brachytherapy (BT). We compared dosimetric outcomes of pulse-dose-rate (PDR) and high-dose-rate (HDR)-BT, according to linear-quadratic model. (Source: Brachytherapy)
Source: Brachytherapy - February 20, 2019 Category: Cancer & Oncology Authors: Pierre Annede, Isabelle Dumas, Antoine Schernberg, Anne Tailleur, Ingrid Fumagalli, Sophie Bockel, Fabien Mignot, Manon Kissel, Eric Deutsch, Christine Haie-meder, Cyrus Chargari Source Type: research

The confidence interval reported in this study appears to be an error
I was excited to read about the results of single fraction high-dose-rate monotherapy for prostate cancer as reported by Prada et  al. The study included 60 patients with a median follow-up of 5 years. The authors report 6-year biochemical control of 82%, which is impressive, but it is difficult for me to believe the reported 95% confidence interval of ±3% at 6 years. I ask the authors to recheck their calculations. (Source: Brachytherapy)
Source: Brachytherapy - February 20, 2019 Category: Cancer & Oncology Authors: W. Robert Lee Source Type: research

Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma
We sought to formally compare Collaborative Ocular Melanoma Study (COMS) and similar-shaped (circular) eye physics (EP) plaques dosimetrically by examining both tumor coverage and critical structure doses. (Source: Brachytherapy)
Source: Brachytherapy - February 20, 2019 Category: Cancer & Oncology Authors: Mary K. Dean, Matthew T. Studenski, Manuel A. Paez-Escamilla, Scott D. Walter, Deukwoo Kwon, Arnold M. Markoe, J. William Harbour, Stuart E. Samuels Source Type: research

Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial
To present the dosimetric results of a Phase II randomized trial comparing dose escalation to the MRI-defined dominant intraprostatic lesion (DIL) using either low-dose-rate (LDR) or high-dose-rate (HDR) prostate brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - February 19, 2019 Category: Cancer & Oncology Authors: Steven Tissaverasinghe, Juanita Crook, Francois Bachand, Deidre Batchelar, Michelle Hilts, Cynthia Araujo, Danielle Anderson, Terry Bainbridge, Brenda Farnquist Source Type: research

Monte Carlo study of the relationship between skin dose and optically stimulated luminescence dosimeter dose in Pd-103 permanent breast seed implant brachytherapy
To establish a method for estimating skin dose for patients with permanent breast seed implant based on in  vivo optically stimulated luminescence dosimeters (OSLDs) measurements. (Source: Brachytherapy)
Source: Brachytherapy - February 18, 2019 Category: Cancer & Oncology Authors: Steven Nich, Charles Kirkby, J. Eduardo Villarreal-Barajas Source Type: research

125I seeds implantation for treating residual hepatocellular carcinoma located beneath the diaphragm after transcatheter arterial chemoembolization
The effect of 125I seed implantation for the treatment of local residual tumor of hepatocellular carcinoma located beneath the diaphragm (HCC-LBD) after transcatheter arterial chemoembolization (TACE) has not yet been reported. This retrospective study was performed to evaluate the safety and efficacy of 125I seeds implantation (ISI) for the treatment of residual HCC-LBD after TACE. (Source: Brachytherapy)
Source: Brachytherapy - February 7, 2019 Category: Cancer & Oncology Authors: Jie Li, Lijuan Zhang, Qigen Xie, Weiguo Wang, Yanyan Hua, Leyuan Zhou, Zongqiong Sun Source Type: research

Factors associated with deformation accuracy and modes of failure for MRI-optimized cervical brachytherapy using deformable image registration
To identify factors associated with MRI-to-CT image deformation accuracy and modes of failure for MRI-optimized intracavitary high-dose-rate treatment of locally advanced cervical cancer. (Source: Brachytherapy)
Source: Brachytherapy - February 7, 2019 Category: Cancer & Oncology Authors: Brandon A. Dyer, Zilong Yuan, Jianfeng Qiu, Stanley H. Benedict, Richard K. Valicenti, Jyoti S. Mayadev, Yi Rong Source Type: research

Understanding the underutilization of cervical brachytherapy for locally advanced cervical cancer
To understand the reasons behind current low utilization of brachytherapy for locally advanced cervical cancer in the United States. (Source: Brachytherapy)
Source: Brachytherapy - February 2, 2019 Category: Cancer & Oncology Authors: Ting Martin Ma, Matthew M. Harkenrider, Catheryn M. Yashar, Akila N. Viswanathan, Jyoti S. Mayadev Source Type: research

Evaluation of bi-objective treatment planning for high-dose-rate prostate brachytherapy —A retrospective observer study
In this study, we investigated the feasibility and plan quality of this method by means of a retrospective observer study. (Source: Brachytherapy)
Source: Brachytherapy - February 1, 2019 Category: Cancer & Oncology Authors: Stefanus C. Maree, Ngoc Hoang Luong, Ernst S. Kooreman, Niek van Wieringen, Arjan Bel, Karel A. Hinnen, Henrike Westerveld, Bradley R. Pieters, Peter A.N. Bosman, Tanja Alderliesten Source Type: research

Optimized penile surface mold brachytherapy using latest stereolithography techniques: A single-institution experience
To describe a technique of penile surface mold high-dose-rate (HDR) brachytherapy and early outcomes. (Source: Brachytherapy)
Source: Brachytherapy - February 1, 2019 Category: Cancer & Oncology Authors: Laura D'Alimonte, Ananth Ravi, Joelle Helou, David Morrison, Lucas C. Mendez, Harry Easton, Gerard Morton Tags: Case Report Source Type: research

Brachytherapy: A critical component of primary radiation therapy for cervical cancer
Brachytherapy is well-established as an integral component in the standard of care for treatment of patients receiving primary radiotherapy for cervical cancer. A decline in brachytherapy has been associated with negative impacts on survival in the era of modern EBRT techniques. Conformal external beam therapies such intensity modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT) should not be used as alternatives to brachytherapy in patients undergoing primary curative-intent radiation therapy for cervical cancer. (Source: Brachytherapy)
Source: Brachytherapy - January 18, 2019 Category: Cancer & Oncology Authors: Christine H. Holschneider, Daniel G. Petereit, Christina Chu, I-Chow Hsu, Yevgeniya J. Ioffe, Ann H. Klopp, Bhavana Pothuri, Lee-may Chen, Catheryn Yashar Tags: Review Article Source Type: research

Correlation between real-time intraoperative and postoperative dosimetry and its implications on intraoperative planning
The purpose of this study was to study the correlation between intraoperative and postimplant dosimetry. We investigated the correlation between prostate (V150) and urethra (D30, D5) dose limits, and whether it is possible to increase prostate D90 and V100 in intraoperative planning without violating postimplant urethra and rectum dose limits. (Source: Brachytherapy)
Source: Brachytherapy - January 14, 2019 Category: Cancer & Oncology Authors: Chenyu Yan, M. Saiful Huq, Dwight E. Heron, Sushil Beriwal, Raymond Wynn Source Type: research

Evaluation of the accuracy of computer-assisted techniques in the interstitial brachytherapy of the deep regions of the head and neck
We sought to investigate the feasibility and accuracy of computer-assisted techniques in the interstitial brachytherapy of the deep regions of the head and neck. (Source: Brachytherapy)
Source: Brachytherapy - January 9, 2019 Category: Cancer & Oncology Authors: Guo-Hao Zhang, Xiao-Ming Lv, Wen-Jie Wu, Zhi-Yuan Wu, Lei Zheng, Ming-Wei Huang, Yong Wang, Jian-Guo Zhang Source Type: research

Long-term oncological and functional outcomes support use of low-dose-rate brachytherapy with or without external beam radiation in young men ( ≤60 years) with localized prostate cancer
To evaluate the oncological and functional outcomes of young men treated with low-dose-rate brachytherapy (BT) for prostate cancer (PCa). (Source: Brachytherapy)
Source: Brachytherapy - January 9, 2019 Category: Cancer & Oncology Authors: Jared S. Winoker, Olamide O. Omidele, Richard G. Stock, Nelson N. Stone Source Type: research

A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer
External beam radiation therapy (EBRT) with low-dose-rate (LDR) brachytherapy boost has been associated with improved biochemical progression –free survival and overall survival (OS) compared with dose-escalated EBRT (DE-EBRT) alone for unfavorable-risk prostate cancer. However, it is not known whether high-dose-rate (HDR) boost provides a similar benefit. We compare HDR boost against LDR boost and DE-EBRT with respect to OS. (Source: Brachytherapy)
Source: Brachytherapy - January 9, 2019 Category: Cancer & Oncology Authors: Martin T. King, David D. Yang, Vinayak Muralidhar, Brandon Mahal, Santino Butler, Phillip M. Devlin, Larissa J. Lee, Kent. W. Mouw, Neil M. Martin, Anthony V. D'Amico, Paul L. Nguyen, Peter F. Orio Source Type: research

Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy
Although current Delphi Consensus guidelines do not recommend a specific definition of biochemical recurrence after partial gland therapy, these guidelines acknowledge that serial prostate-specific antigen (PSA) tests remain the best marker for monitoring disease after treatment. The purpose of this study was to determine whether PSA velocity at failure per the Phoenix (nadir  + 2 ng/mL) definition is associated with metastasis and prostate cancer-specific mortality (PCSM) in a cohort of patients who experienced PSA failure after partial gland therapy. (Source: Brachytherapy)
Source: Brachytherapy - January 9, 2019 Category: Cancer & Oncology Authors: Martin T. King, Paul L. Nguyen, Ninjin Boldbaatar, David D. Yang, Vinayak Muralidhar, Clare M. Tempany, Robert A. Cormack, Mark D. Hurwitz, W. Warren Suh, Mark M. Pomerantz, Anthony V. D'Amico, Peter F. Orio Source Type: research

Dosimetric study of CO-60 source step size in uterine cervix intracavitary HDR brachytherapy
The present work reports effects of source step sizes on dose distribution in patients treated with cobalt-60 (Co-60) high-dose-rate afterloading brachytherapy in carcinoma cervix (Ca-cx). (Source: Brachytherapy)
Source: Brachytherapy - January 4, 2019 Category: Cancer & Oncology Authors: Arvind Kumar Shukla, Bhupendra Singh Rana, Narinder Paul Singh, Sanjeev Kumar Source Type: research

Editorial Board
(Source: Brachytherapy)
Source: Brachytherapy - January 1, 2019 Category: Cancer & Oncology Source Type: research

Masthead
(Source: Brachytherapy)
Source: Brachytherapy - January 1, 2019 Category: Cancer & Oncology Source Type: research

Table of Contents
(Source: Brachytherapy)
Source: Brachytherapy - January 1, 2019 Category: Cancer & Oncology Source Type: research

Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
To evaluate the effect of metabolic parameters of pretreatment primary tumor and regional lymph nodes with F-18-FDG PET/CT compared with MRI findings for the prognostic value and disease-free survival (DFS) in locally advanced cervical cancer. (Source: Brachytherapy)
Source: Brachytherapy - December 26, 2018 Category: Cancer & Oncology Authors: Zedef Dag, Burcak Yilmaz, Ayse Kutluhan Dogan, Donay Unluer Aksan, Huseyin Ozkurt, Hazim Orhan K ızılkaya, Deniz Arslan Source Type: research

Use of interstitial brachytherapy in pelvic recurrence of cervical carcinoma: Clinical response, survival, and toxicity
The purpose of this study was to evaluate clinical response, postrecurrence survival, disease-free survival (DFS), and toxicity related to reirradiation in pelvic recurrence of cervical carcinoma. (Source: Brachytherapy)
Source: Brachytherapy - December 24, 2018 Category: Cancer & Oncology Authors: Vinicius Toloti Moschini da Silva, Ana Paula Fortuna Diniz, Jumara Martins, Kleber Cursino, Sergio Carlos Barros Esteves, Julio Cesar Teixeira Source Type: research

MRI-guided adaptive brachytherapy for locally advanced cervix cancer: Treatment outcomes from a single institution in Hong Kong
Paradigm has shifted from 2D to image-guided adaptive brachytherapy (IGABT) for locally advanced cervix cancer (LACC). Increasing reports from pioneering institutions and large retrospective multicenter series have demonstrated improvements in outcome and reduction in toxicity with IGABT. However, there is scarcity of data on magnetic resonance (MR)-IGABT in Chinese patients. (Source: Brachytherapy)
Source: Brachytherapy - December 20, 2018 Category: Cancer & Oncology Authors: Philip Yuguang Wu, Terry Pang Wai Wong, Yan Yee Chloe Yip, Tien Yee Amy Chang, Lai Kwan Lucy Chan, Michael Chi Hang Lee, Lai Yau Ada Law, Mei Wan Rebecca Yeung, Sung Inda Soong Source Type: research

Brachytherapy and survival in small cell cancer of the cervix and uterus
Small cell cancer involving the cervix and uterus is considered the same rare disease, but management is controversial and disparate. Patterns of care and outcomes in the United States are unclear. (Source: Brachytherapy)
Source: Brachytherapy - December 15, 2018 Category: Cancer & Oncology Authors: Alexander J. Lin, Comron Hassanzadeh, Stephanie Markovina, Julie Schwarz, Perry Grigsby Source Type: research

Long-term results of multicatheter interstitial high-dose-rate brachytherapy for accelerated partial-breast irradiation
The purpose of this study was to report the long-term results of women treated in one center with accelerated partial-breast irradiation (APBI) with interstitial high-dose-rate (HDR) brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - December 13, 2018 Category: Cancer & Oncology Authors: Marc Gaudet, Mathieu Pharand-Charbonneau, Debbie Wright, Jonathan Nguyen, Jade Trudel-Sabourin, Mustapha Chelfi Source Type: research

Development and dosimetric assessment of a patient-specific elastic skin applicator for high-dose-rate brachytherapy
The purpose of this study was to develop a patient-specific elastic skin applicator and to evaluate its dosimetric characteristics for high-dose-rate (HDR) brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - December 6, 2018 Category: Cancer & Oncology Authors: So-Yeon Park, Seonghee Kang, Jong Min Park, Hyun Joon An, Do Hoon Oh, Jung-in Kim Source Type: research

Subcutaneous spacer injection to reduce skin toxicity in breast brachytherapy: A pilot study on mastectomy specimens
Accelerated partial breast irradiation is a treatment option for selected patients with early-stage breast cancer. Some accelerated partial breast irradiation techniques lead to skin toxicity with the skin dose as a main risk factor. Biodegradable spacers are effective and safe in prostate brachytherapy to protect the rectum. We hypothesize that a subcutaneous spacer injection reduces the skin dose in breast brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - December 5, 2018 Category: Cancer & Oncology Authors: Gerson M. Struik, Jean-Philippe Pignol, Inger-Karine Kolkman-Deurloo, Jeremy Godart, Gerda M. Verduijn, Linetta B. Koppert, Erwin Birnie, Ali Ghandi, Taco M. Klem Source Type: research

Patient-reported sexual adjustment after definitive chemoradiation and MR-guided brachytherapy for cervical cancer
The treatment of locally advanced cervical cancer with definitive chemoradiation (CRT) is associated with vaginal toxicity and altered sexual satisfaction. This prospective study assessed patient-reported sexual adjustment, vaginal dosimetry, and physician-reported vaginal toxicity in patients with cervical cancer treated with CRT and MR-guided brachytherapy (BT). (Source: Brachytherapy)
Source: Brachytherapy - November 30, 2018 Category: Cancer & Oncology Authors: Jessica L. Conway, Rachel Gerber, Kathy Han, Haiyan Jiang, Jason Xie, Akbar Beiki-Ardakani, Anthony Fyles, Michael Milosevic, Deborah Williamson, Jennifer Croke Source Type: research

Risk analysis of electronic intraoperative radiation therapy for breast cancer
To evaluate the process and improve safety of intraoperative radiation therapy (IORT) for early-stage breast cancers treated with electronic brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - November 29, 2018 Category: Cancer & Oncology Authors: Dominique Rash, David Hoffman, Ryan Manger, Irena Dragojevi ć Source Type: research

Impact on treatment time of MRI-based brachytherapy in two implants (4 doses) compared with CT-based brachytherapy in five implants for cervical cancer
Concurrent chemoradiotherapy and brachytherapy is the standard of care for locally advanced cervical cancer. Brachytherapy is an integral part of treatment and has improved overall survival. Research is needed to ascertain the planning modalities and schedules to best use resources and optimize treatment time course. We hypothesized that MRI-based brachytherapy when delivered with the described regimen would not prolong, and potentially shorten, overall treatment time as compared with CT-based brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - November 26, 2018 Category: Cancer & Oncology Authors: Christina Small, Grant Harmon, John Weaver, Vince Vivirito, Ramon Durazo-Arvizu, William Small, Matthew M. Harkenrider Source Type: research

The American Brachytherapy Society consensus statement for electronic brachytherapy
Brachytherapy is utilized in the treatment of many different malignancies; although traditionally performed with low-dose-rate or high-dose-rate techniques, more recently, electronic brachytherapy (EB) has emerged as a potential alternative. At this time, there are no evidence-based guidelines to assist clinicians in patient selection for EB and concerns exits regarding differences in dosimetry as compared to traditional brachytherapy techniques. As such, the American Brachytherapy Society appointed a group of physicians and physicists to create a consensus statement regarding the use of EB. (Source: Brachytherapy)
Source: Brachytherapy - November 26, 2018 Category: Cancer & Oncology Authors: Martin C. Tom, Jaroslaw T. Hepel, Rakesh Patel, Mitchell Kamrava, Shahed N. Badiyan, Gil'ad N. Cohen, Chirag Shah Tags: Review Article Source Type: research

Predictive factors of benefit from iodine-125 brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis
The aims of this study were to evaluate treatment responses and predictive factors for overall survival (OS) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) treated with iodine-125 (125I) brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - November 19, 2018 Category: Cancer & Oncology Authors: Junqing Lin, Han Jiang, Weizhu Yang, Na Jiang, Qubin Zheng, Ning Huang, Xiaolong Wang, Ang Li, Jingyao Huang Source Type: research

Prostate brachytherapy under hypnosedation: A prospective evaluation
Hypnosedation (HS) for brachytherapy has been proposed in patients with prostate cancer and has been evaluated. (Source: Brachytherapy)
Source: Brachytherapy - November 10, 2018 Category: Cancer & Oncology Authors: Olivier Chapet, Corina Udrescu, Samy Horn, Alain Ruffion, Fabrice Lorchel, Sonya Gaudioz, C écile Clamens, Vincent Piriou, Edwige Rigal Source Type: research

Individualized 3D-printed templates for high-dose-rate interstitial multicathether brachytherapy in patients with breast cancer
High-dose-rate, multicatheter interstitial brachytherapy is technically complex and operator-dependent, requiring lengthy training and specialized skills. Furthermore, until the advent of contouring on computerized tomography (CT) images, difficulties existed in locating the target volume precisely. The present article reports the results of a study that aimed at producing and validating a 3D-printed template to aid in target volume localization for multicatheter interstitial brachytherapy in patients with breast cancer. (Source: Brachytherapy)
Source: Brachytherapy - November 7, 2018 Category: Cancer & Oncology Authors: Cynthia Aristei, Valentina Lancellotta, Marco Piergentini, Giacomo Costantini, Simonetta Saldi, Sara Chierchini, Antonella Cavalli, Luca Di Renzo, Oscar Fiorucci, Massimo Guasticchi, Vittorio Bini, Alessandro Ricci Source Type: research

A systematic review comparing radiation toxicity after various endorectal techniques
A clinical complete response is seen after neoadjuvant chemoradiation for rectal tumors in 15% –20% of patients. These patients can potentially be spared mutilating total mesorectal excision surgery through a watch-and-wait policy. Recent studies show that dose escalation by a radiation boost increases the clinical complete response rate. The boost dose to the tumor can be administered thro ugh external beam radiotherapy or through internal radiotherapy using techniques like contact therapy, low-dose-rate or high-dose-rate brachytherapy (BT). (Source: Brachytherapy)
Source: Brachytherapy - November 2, 2018 Category: Cancer & Oncology Authors: An-Sofie Verrijssen, Thirza Opbroek, Murillo Bellezzo, Gabriel P. Fonseca, Frank Verhaegen, Jean-Pierre Gerard, Arthur Sun Myint, Evert J. Van Limbergen, Maaike Berbee Tags: Review Article Source Type: research

Improving brachytherapy efficiency with dedicated dosimetrist planners
To investigate the different factors affecting the procedure duration for high-dose-rate brachytherapy for gynecologic malignancies. (Source: Brachytherapy)
Source: Brachytherapy - November 1, 2018 Category: Cancer & Oncology Authors: Dylann K. Fujimoto, Rie von Eyben, Melissa Usoz, Elizabeth A. Kidd Source Type: research

Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial
In the article, Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a phase II trial (Brachytherapy, Volume 17, Issue 5, Pages 734 –741, 2018), by Martinez-Monge R et al., the authors did not include their acknowledgment statement: “The authors wish to thank Mr. David Carpenter for editorial assistance. This work was supported by the Fondo de Investigaciones Sanitarias to R.M-M (PI 16/01847)”. (Source: Brachytherapy)
Source: Brachytherapy - November 1, 2018 Category: Cancer & Oncology Authors: Rafael Mart ínez-Monge, Germán Valtueña Peydró, Mauricio Cambeiro, José Manuel Aramendía, Marta Gimeno, Marta Santisteban, Fernando Lecanda, Jose Angel Minguez, Juan L. Alcázar, Matías Jurado Tags: Corrigendum Source Type: research

Reviewers Listing 2018
(Source: Brachytherapy)
Source: Brachytherapy - November 1, 2018 Category: Cancer & Oncology Source Type: research

Editorial Board
(Source: Brachytherapy)
Source: Brachytherapy - November 1, 2018 Category: Cancer & Oncology Source Type: research

Masthead
(Source: Brachytherapy)
Source: Brachytherapy - November 1, 2018 Category: Cancer & Oncology Source Type: research

Table of Contents
(Source: Brachytherapy)
Source: Brachytherapy - November 1, 2018 Category: Cancer & Oncology Source Type: research